EP1785137A4 - Medicament contre l'hyperlipemie - Google Patents

Medicament contre l'hyperlipemie

Info

Publication number
EP1785137A4
EP1785137A4 EP05777087A EP05777087A EP1785137A4 EP 1785137 A4 EP1785137 A4 EP 1785137A4 EP 05777087 A EP05777087 A EP 05777087A EP 05777087 A EP05777087 A EP 05777087A EP 1785137 A4 EP1785137 A4 EP 1785137A4
Authority
EP
European Patent Office
Prior art keywords
hyperlipemia
remedy
pitavastatin
ezetimibe
hypercholesterolemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05777087A
Other languages
German (de)
English (en)
Other versions
EP1785137B1 (fr
EP1785137A1 (fr
Inventor
Taro Aoki
Hiroyuki Yamazaki
Takashi Maejima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Nissan Chemical Corp
Original Assignee
Kowa Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35944235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1785137(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kowa Co Ltd, Nissan Chemical Corp filed Critical Kowa Co Ltd
Priority to PL05777087T priority Critical patent/PL1785137T3/pl
Publication of EP1785137A1 publication Critical patent/EP1785137A1/fr
Publication of EP1785137A4 publication Critical patent/EP1785137A4/fr
Application granted granted Critical
Publication of EP1785137B1 publication Critical patent/EP1785137B1/fr
Priority to CY20111100106T priority patent/CY1111150T1/el
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
EP05777087A 2004-08-31 2005-08-30 Medicament contre l'hyperlipemie Revoked EP1785137B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL05777087T PL1785137T3 (pl) 2004-08-31 2005-08-30 Środek do leczenia hiperlipemii
CY20111100106T CY1111150T1 (el) 2004-08-31 2011-02-01 Θεραπεια για υπερλιπαιμια

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60552504P 2004-08-31 2004-08-31
US10/997,878 US20060046996A1 (en) 2004-08-31 2004-11-29 Method for treating hyperlipidemia
PCT/JP2005/015756 WO2006025378A1 (fr) 2004-08-31 2005-08-30 Medicament contre l'hyperlipemie

Publications (3)

Publication Number Publication Date
EP1785137A1 EP1785137A1 (fr) 2007-05-16
EP1785137A4 true EP1785137A4 (fr) 2007-12-19
EP1785137B1 EP1785137B1 (fr) 2010-11-24

Family

ID=35944235

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05777087A Revoked EP1785137B1 (fr) 2004-08-31 2005-08-30 Medicament contre l'hyperlipemie

Country Status (13)

Country Link
US (2) US20060046996A1 (fr)
EP (1) EP1785137B1 (fr)
JP (1) JP4886516B2 (fr)
KR (1) KR101244508B1 (fr)
CN (1) CN101010080B (fr)
AT (1) ATE489093T1 (fr)
CY (1) CY1111150T1 (fr)
DE (1) DE602005024981D1 (fr)
ES (1) ES2354366T3 (fr)
HK (1) HK1110200A1 (fr)
PL (1) PL1785137T3 (fr)
PT (1) PT1785137E (fr)
WO (1) WO2006025378A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
JP4719572B2 (ja) * 2003-04-17 2011-07-06 興和株式会社 Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
SA04250427A (ar) * 2003-12-23 2005-12-03 استرازينيكا ايه بي مشتقات ثاني فينيل أزيتيدون
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US20130023513A1 (en) * 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
WO2020178878A1 (fr) * 2019-03-01 2020-09-10 興和株式会社 Composition pharmaceutique
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006072881A1 (fr) * 2005-01-10 2006-07-13 Cortendo Invest Ab Procedes et compositions pour le traitement du diabete, du syndrome metabolique et d'autres conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854259A (en) * 1987-08-20 1998-12-29 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5185328A (en) * 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6465477B1 (en) * 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006072881A1 (fr) * 2005-01-10 2006-07-13 Cortendo Invest Ab Procedes et compositions pour le traitement du diabete, du syndrome metabolique et d'autres conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIS HARRY R JR ET AL: "The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs", METABOLISM CLINICAL AND EXPERIMENTAL, vol. 50, no. 10, October 2001 (2001-10-01), pages 1234 - 1241, XP002456587, ISSN: 0026-0495 *
GAGNE C ET AL: "EFFICACY AND SAFETY OF EZETIMIBE ADDED TO ONGOING STATIN THERAPY FOR TREATMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA,, US, vol. 90, no. 10, 15 November 2002 (2002-11-15), pages 1084 - 1091, XP008011770, ISSN: 0002-9149 *

Also Published As

Publication number Publication date
PT1785137E (pt) 2010-12-23
HK1110200A1 (en) 2008-07-11
KR101244508B1 (ko) 2013-03-18
EP1785137B1 (fr) 2010-11-24
CN101010080B (zh) 2011-02-09
US20060046996A1 (en) 2006-03-02
CY1111150T1 (el) 2015-06-11
ES2354366T3 (es) 2011-03-14
US7459447B2 (en) 2008-12-02
PL1785137T3 (pl) 2011-04-29
ATE489093T1 (de) 2010-12-15
US20070032467A1 (en) 2007-02-08
EP1785137A1 (fr) 2007-05-16
CN101010080A (zh) 2007-08-01
DE602005024981D1 (de) 2011-01-05
WO2006025378A1 (fr) 2006-03-09
JP4886516B2 (ja) 2012-02-29
KR20070047766A (ko) 2007-05-07
JPWO2006025378A1 (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
HK1110200A1 (en) Remedy for hyperlipemia
NO20050073L (no) Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene
CY2019030I2 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
AU2003251563A1 (en) Implatable or insertable medical devices for controlled delivery of a therapeutic agent
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2005002515A3 (fr) Administration de composes therapeutiques au cerveau et a d'autres tissus
MY176938A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof
ATE257480T1 (de) Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren
WO2005044192A3 (fr) Composes triazole et utilisations associees
WO2009005269A3 (fr) Composition pharmaceutique contenant des dérivés d'isoxazole destinée à prévenir et à traiter la resténose
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
AU2002366355A1 (en) SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
HK1137142A1 (en) Drug for treatment of influenza
ATE360633T1 (de) N-substituierte hydromorphone und ihre anwendung
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
EP1753425A4 (fr) Agent therapeutique comprenant un acide nicotinique ou ses derives en tant qu'ingredient efficace, destine a la prevention ou au traitement du cancer
ZA200609337B (en) Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
CA2449922A1 (fr) Composition pharmaceutique pour therapie de la cystite interstitielle
AU2001263383A1 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
WO2006033891A3 (fr) Composes pour traitement de la dyslipidemie et autres troubles lipidiques
AU2003210659A1 (en) Combination therapy for treatment of hiv infection
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
ATE469642T1 (de) Vorbeugungs- oder heilmittel gegen endometriose
WO2003089449A3 (fr) Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective
BRPI0417747A (pt) uso de compostos orgánicos

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071120

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/47 20060101AFI20060719BHEP

Ipc: A61K 31/397 20060101ALI20071109BHEP

Ipc: A61P 3/06 20060101ALI20071109BHEP

Ipc: A61K 31/4709 20060101ALI20071109BHEP

17Q First examination report despatched

Effective date: 20080402

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YAMAZAKI, HIROYUKI

Inventor name: MAEJIMA, TAKASHI

Inventor name: AOKI, TARO

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20101216

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REF Corresponds to:

Ref document number: 602005024981

Country of ref document: DE

Date of ref document: 20110105

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Effective date: 20110302

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: NISSAN CHEMICAL INDUSTRIES, LTD.

Free format text: NISSAN CHEMICAL INDUSTRIES, LTD.#7-1, KANDA NISHIKI-CHO 3-CHOME#CHIYODA-KU, TOKYO 101-0054 (JP) $ KOWA COMPANY, LTD.#6-29, NISHIKI 3-CHOME, NAKA-KU,#NAGOYA-SHI, AICHI-KEN 460-8625 (JP) -TRANSFER TO- NISSAN CHEMICAL INDUSTRIES, LTD.#7-1, KANDA NISHIKI-CHO 3-CHOME#CHIYODA-KU, TOKYO 101-0054 (JP) $ KOWA COMPANY, LTD.#6-29, NISHIKI 3-CHOME, NAKA-KU,#NAGOYA-SHI, AICHI-KEN 460-8625 (JP)

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20110400402

Country of ref document: GR

Effective date: 20110317

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110224

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110324

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

26 Opposition filed

Opponent name: MERCK SHARP & DOHME CORP.

Effective date: 20110823

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20110824

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602005024981

Country of ref document: DE

Effective date: 20110823

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20120823

Year of fee payment: 8

Ref country code: GB

Payment date: 20120823

Year of fee payment: 8

Ref country code: IE

Payment date: 20120821

Year of fee payment: 8

Ref country code: FI

Payment date: 20120822

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20120817

Year of fee payment: 8

Ref country code: GR

Payment date: 20120821

Year of fee payment: 8

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20120831

Year of fee payment: 8

Ref country code: DE

Payment date: 20120802

Year of fee payment: 8

Ref country code: ES

Payment date: 20120824

Year of fee payment: 8

Ref country code: IT

Payment date: 20120828

Year of fee payment: 8

Ref country code: FR

Payment date: 20120831

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20120821

Year of fee payment: 8

Ref country code: PT

Payment date: 20120229

Year of fee payment: 8

Ref country code: NL

Payment date: 20120824

Year of fee payment: 8

APAW Appeal reference deleted

Free format text: ORIGINAL CODE: EPIDOSDREFNO

APAY Date of receipt of notice of appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDNOA2O

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120822

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110830

REG Reference to a national code

Ref country code: DE

Ref legal event code: R103

Ref document number: 602005024981

Country of ref document: DE

Ref country code: DE

Ref legal event code: R064

Ref document number: 602005024981

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

REG Reference to a national code

Ref country code: PT

Ref legal event code: MP4A

Effective date: 20131112

Ref country code: CH

Ref legal event code: PL

27W Patent revoked

Effective date: 20130928

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20130928

REG Reference to a national code

Ref country code: DE

Ref legal event code: R107

Ref document number: 602005024981

Country of ref document: DE

Effective date: 20140116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20101124

Ref country code: CH

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20101124

REG Reference to a national code

Ref country code: AT

Ref legal event code: MA03

Ref document number: 489093

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130928

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130830

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130830

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130831